VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in <i>Enterobacterales</i> and Pseudomonas aeruginosa
Jodie C. Hamrick(VenatoRx Pharmaceuticals (United States)), Jean‐Denis Docquier(University of Siena), Tsuyoshi Uehara(VenatoRx Pharmaceuticals (United States)), Cullen L. Myers(VenatoRx Pharmaceuticals (United States)), David A. Six(VenatoRx Pharmaceuticals (United States)), Cassandra L. Chatwin(VenatoRx Pharmaceuticals (United States)), Kaitlyn John(VenatoRx Pharmaceuticals (United States)), Salvador Vernacchio(VenatoRx Pharmaceuticals (United States)), Susan M. Cusick(VenatoRx Pharmaceuticals (United States)), Robert E. Lee Trout(VenatoRx Pharmaceuticals (United States)), Cecilia Pozzi(University of Siena), Filomena De Luca(University of Siena), Manuela Benvenuti(University of Siena), Stefano Mangani(University of Siena), Bin Liu(VenatoRx Pharmaceuticals (United States)), Randy W. Jackson(VenatoRx Pharmaceuticals (United States)), Greg Moeck(VenatoRx Pharmaceuticals (United States)), L Xerri(VenatoRx Pharmaceuticals (United States)), Christopher J. Burns(VenatoRx Pharmaceuticals (United States)), Daniel C. Pevear(VenatoRx Pharmaceuticals (United States)), Denis M. Daigle(VenatoRx Pharmaceuticals (United States))
Cited by 212Open Access
Abstract
s of 1 and 4 μg/ml, respectively, representing ≥256- and ≥32-fold improvements, respectively, in antibacterial activity over that of cefepime alone. The data demonstrate the potent, broad-spectrum rescue of cefepime activity by taniborbactam against clinical isolates of CRE and CRPA.
Related Papers
No related papers found
Powered by citation graph analysis